XML 33 R23.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies (Narrative) (Details)
3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
item
Mar. 31, 2019
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
item
Feb. 29, 2020
USD ($)
Summary Of Significant Accounting Policies [Line Items]            
Fair value of the financing derivative   $ 0     $ 0  
Financing derivative   $ 0
Proceeds from Continuation Advances 34,000,000 $ 18,000,000.0   52,000,000.0    
Deferred gain from Reverse Termination Fee $ 98,000,000     98,000,000    
Period in which company must repay continuation advances if change-of-controll transaction is entered into with third party 2 years          
Equity or debt financing that must be raised in a single transaction $ 100,000,000          
Period in which company must raise equity or debt financing in a single transaction 2 years          
Contingent repayment liability $ 0     $ 0    
Gain from Continuation Advances 34,000,000       $ 18,000,000.0  
Fair value assets/liabilities transfer between levels $ 0          
Measurement Input, Discount Rate [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Derivative liability, measurement input | item   0.065     0.065  
Sales Revenue, Net [Member] | TOMY Digital Biology Co. [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Concentration risk, percentage 11.00%          
Sales Revenue, Net [Member] | Gene Company Limited [Member]            
Summary Of Significant Accounting Policies [Line Items]            
Concentration risk, percentage     17.00%